These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25034785)

  • 21. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
    Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
    Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.
    Gilormini M; Malesys C; Armandy E; Manas P; Guy JB; Magné N; Rodriguez-Lafrasse C; Ardail D
    Oncotarget; 2016 Mar; 7(13):16731-44. PubMed ID: 26934442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
    Stauffer SR
    Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas.
    Huang WC; Kuo KT; Adebayo BO; Wang CH; Chen YJ; Jin K; Tsai TH; Yeh CT
    J Nutr Biochem; 2018 Apr; 54():140-150. PubMed ID: 29414668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production.
    Bessou M; Lopez J; Gadet R; Deygas M; Popgeorgiev N; Poncet D; Nougarède A; Billard P; Mikaelian I; Gonzalo P; Rimokh R; Gillet G
    Oncogene; 2020 Apr; 39(15):3056-3074. PubMed ID: 32066881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity.
    Park HA; Licznerski P; Mnatsakanyan N; Niu Y; Sacchetti S; Wu J; Polster BM; Alavian KN; Jonas EA
    Cell Death Differ; 2017 Nov; 24(11):1963-1974. PubMed ID: 28777375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
    Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-xL is an oncogenic driver in colorectal cancer.
    Scherr AL; Gdynia G; Salou M; Radhakrishnan P; Duglova K; Heller A; Keim S; Kautz N; Jassowicz A; Elssner C; He YW; Jaeger D; Heikenwalder M; Schneider M; Weber A; Roth W; Schulze-Bergkamen H; Koehler BC
    Cell Death Dis; 2016 Aug; 7(8):e2342. PubMed ID: 27537525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
    Gardner EE; Connis N; Poirier JT; Cope L; Dobromilskaya I; Gallia GL; Rudin CM; Hann CL
    Cancer Res; 2014 May; 74(10):2846-56. PubMed ID: 24614082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
    Chen J; Zhou H; Aguilar A; Liu L; Bai L; McEachern D; Yang CY; Meagher JL; Stuckey JA; Wang S
    J Med Chem; 2012 Oct; 55(19):8502-14. PubMed ID: 23030453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.